Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment Registry of Alecensa in Korean Patients With Anaplastic Lymphoma Kinase (ALK)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT03271554 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT03271554
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03271554 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment Registry of Alecensa in Korean Patients With Anaplastic Lymphoma Kinase (ALK)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Lead sponsor
Hoffmann-La Roche
Phase
Observational
Overall status
Completed
Start date
November 9, 2017
Completion date
May 28, 2021
Enrollment
355 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer